McIlrath & Eck’s Editas Medicine EDIT Stock Holding History

McIlrath & Eck’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-140	Closed	-$2K	–	897
2022 Q3	$2K	Hold	140	–	–	﹤0.01%	753
2022 Q2	$2K	Hold	140	–	–	﹤0.01%	734
2022 Q1	$3K	Sell	140 -320	-70%	-$5.95K	﹤0.01%	692
2021 Q4	$12K	Hold	460	–	–	﹤0.01%	503
2021 Q3	$19K	Hold	460	–	–	0.01%	401
2021 Q2	$26K	Hold	460	–	–	0.01%	346
2021 Q1	$19K	Hold	460	–	–	0.01%	351
2020 Q4	$32K	Hold	460	–	–	0.01%	227
2020 Q3	$13K	Hold	460	–	–	0.01%	333
2020 Q2	$14K	Hold	460	–	–	0.01%	295
2020 Q1	$9K	Hold	460	–	–	0.01%	321
2019 Q4	$14K	Buy	460 +320	+229%	+$7.99K	0.01%	298
2019 Q3	$3K	Buy	+140	New	+$3.47K	﹤0.01%	522

Other funds holding EDIT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

McIlrath & Eck's EDIT Position: Q4 2022 in Review

McIlrath & Eck sold out of Editas Medicine (EDIT) in Q4 2022, closing a stake of 140 shares — an estimated $2K sold.

McIlrath & Eck first reported a position in EDIT in Q3 2019 and held it in 13 quarters. The position peaked at $32K in Q4 2020. 250 funds tracked by Wall St. Rank hold EDIT as of Q4 2022.

McIlrath & Eck reported no remaining Editas Medicine position as of Q4 2022 after selling out during the quarter.
McIlrath & Eck sold 140 Editas Medicine shares in Q4 2022, an estimated $2K.
McIlrath & Eck first reported a position in Editas Medicine in Q3 2019 and held it in 13 quarters.
McIlrath & Eck's Editas Medicine position peaked at $32K in Q4 2020.
250 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2022.

Based on McIlrath & Eck's 13F filing for Q4 2022, filed 15 Feb 2023.